Citi analyst Daniel Grosslight initiated coverage of AmerisourceBergen with a Buy rating and $185 price target. The analyst started the drug distribution sector with a positive bias, naming McKesson its top pick and AmerisourceBergen a "close second." The firm views the sector as safe haven in the currently challenged macro environment, with "unrivaled" cash generation and return on invested capital profiles. The big three distributors should be able to offset headwinds from generic price deflation and waning pandemic tailwinds to deliver high single-digit to low double-digit EBIT, contends Citi.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABC:
- Early notable gainers among liquid option names on February 17th
- AmerisourceBergen price target raised to $201 from $199 at Baird
- AmerisourceBergen price target raised to $170 from $162 at Mizuho
- AmerisourceBergen raises FY23 adjusted EPS view to $11.50-$11.75
- AmerisourceBergen reports Q1 adjusted EPS $2.71, consensus $2.63